• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

  • — 10 Dec, 2007
AudioMedica News
AudioMedica News
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
00:00 /
RSS Feed
Share
Link
Embed
Susan O’Brien
Susan O’Brien

SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.

Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_susan_o_brien.mp3]

You may also like...

  • Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome 28 Sep, 2009
  • Stephen Hodi Combination immunotherapy improved overall survival in patients with metastatic melanoma 15 Sep, 2013
  • Jorge Cortes Chronic myeloid leukaemia: third generation TKI, ponatinib, succeeds against the T 315 I mutation 18 Dec, 2012
  • Audio Journal of Oncology in Advance – March 1st, 2008 Audio Journal of Oncology in Advance – March 1st, 2008 4 Mar, 2008
  • Previous story Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
  • Next story Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
  • News

    • Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”August 4, 2022
    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • New Front Line Standard for Older Patients with Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Which Tasks Most Influence Pediatric PT Productivity,…
  • Home
  • Oncology
  • Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.